



## Akouos to Participate in Upcoming February Virtual Investor Conferences

January 31, 2022

BOSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. ("Akouos") (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that members of the management team will participate in two upcoming virtual investor conferences in February:

- **Cowen 2<sup>nd</sup> Annual Genetic Medicines Summit.** Panel discussion including Stacy Price, M.S., chief technical officer, titled "Hot Topics in CMC/Manufacturing of Genetic Medicines" on Thursday, February 3 at 2:00 p.m. EST
- **11<sup>th</sup> Annual SVB Leerink Global Healthcare Conference 2022.** Presentation by Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer, on Wednesday, February 16 at 3:00 p.m. EST

A live webcast of the SVB Leerink presentation will be accessible through the investors section of [www.akouos.com](http://www.akouos.com). To access the webcast, please go to the Akouos website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. An archived replay will be available on Akouos's website for 30 days following the conference.

### About Akouos

Akouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for individuals living with disabling hearing loss worldwide. Leveraging its precision genetic medicine platform that incorporates a proprietary adeno-associated viral (AAV) vector library and a novel delivery approach, Akouos is focused on developing precision therapies for forms of sensorineural hearing loss. Headquartered in Boston, Akouos was founded in 2016 by leaders in the fields of neurotology, genetics, inner ear drug delivery, and AAV gene therapy.

### Contacts

#### Media:

Katie Engleman, 1AB  
katie@1abmedia.com

#### Investors:

Courtney Turiano, Stern Investor Relations  
Courtney.Turiano@sternir.com